肿瘤细胞治疗研究
英文原题：Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.
胶质母细胞瘤是全球中枢神经系统恶性肿瘤领域的一大挑战。
胶质母细胞瘤是全球中枢神经系统恶性肿瘤领域的一大严峻挑战。GBM固有的异质性，以及免疫抑制性肿瘤微环境的形成，支持其对当前治疗方法的耐药性。近年来，免疫治疗方法已成为潜在的选项。然而，由于传统免疫治疗技术的固有局限，需要创新性方法。前沿技术的进步为提升效应细胞效力提供了可能的途径。本综述深入探讨GBM中复杂的免疫抑制通路，特别强调CAR T/NK细胞治疗作为一种潜在成就。认识并解决这些问题可能为更有效、更有针对性的胶质母细胞瘤治疗开辟道路，以改善患者预后为目标为未来带来希望。此外，本综述为将纳米技术整合到CAR T/NK细胞治疗中以增强这些个性化基因治疗产品的效率提供了有价值的见解。
Glioblastoma is a strong challenge in the worldwide field of central nervous system malignancies. GBM's inherent heterogeneity, along with the formation of an immunosuppressive tumor microenvironment, supports its resistance to current therapy methods. Immunotherapeutic methods have emerged as potential options in recent years. However, because of the inherent limits of traditional immunotherapeutic techniques innovative approaches are required. Advances in cut-edge techniques provide a possible route for improving effector cell effectiveness. This review gives insight into the complicated immunosuppressive pathways in GBM, with a particular emphasis on CAR T/NK-cell treatment as a potential achievement. Recognizing and addressing these concerns might open the way for more effective and focused glioblastoma therapies, providing hope for the future with the aim of improved outcomes for patients. In addition, this review presents valuable insights into the integration of nanotechnology into CAR T/NK cell therapy for enhanced efficiency of these personalized gene therapy products.
MEMBER ACCOUNT
登录成功会直接打开下一页。
